CHRONIC ASTHMA GUIDELINES IN ADOLESCENTS & ADULTS 2007

1. CHRONIC ASTHMA GUIDELINESIN ADOLESCENTS & ADULTS 2007 Bushra A. Hadi Asthma Guidelines Implementation Project

2. Guidelines for the management of chronic asthma in adolescents and adults

3. Levels of Evidence

4. Aims of the Guideline • to improve asthma care for the greatest number through uniform treatment protocols • to use the most efficacious and cost-effective drug combinations • to facilitate teaching of doctors and other health care workers • to empower patients to understand their disorder, and the types & goals of therapy

5. Key Features of New Guidelines • Emphasis on defining & achieving control of asthma • The positioning of leukotriene blockers in the treatment of chronic asthma • New evidence on the safety & optimal use of asthma medications • The ongoing need to emphasize the use of anti-inflammatory medication as the foundation of asthma treatment

6. 2006 GINA Goalsof Asthma Management • Achieve and maintain control of symptoms • Maintain normal activity levels including exercise • Maintain pulmonary function as close to normal as possible • Prevent asthma exacerbations • Avoid adverse effects from asthma medications • Prevent asthma mortality • a • b • c • d • e • f

7. Essential steps in the Management of Asthma to Achieve Control: • Establish the diagnosis of asthma • Assess severity • Implement asthma treatment • Set goals for control of asthma • Prevent/avoidance measures • Pharmacotherapy • Achieve and monitor control • a • b • c • d

8. A.ASTHMA DIAGNOSIS

9. STEP 1 • Suspect asthma on basis of symptoms and signs, particularly if there is variability

10. STEP 2 • Search for associated factors such as: • a. Atopy - allergic rhinitis, conjunctivitis, eczema • b. Family history of asthma or other allergic disorders • c. Onset of, or presence of, symptoms during childhood • d. Identifiable triggers for symptoms and relieving factors such as improvement with a bronchodilator or deterioration with exercise • e. Exposure to known asthma sensitizers in the workplace • f. Reversibility shown on lung function tests • g. Optional tests include: • Full blood count to check the eosinophil count • Total serum IgE • Skin prick tests or RAST in blood to look for evidence of atopy • Methacholine or histamine or exercise challenge tests

11. Diagnostic lung function values • Reversibility: • An increase of FEV1 of >12% and 200ml, 15-30min after the • inhalation of 200-400mcg salbutamol, or a 20% improvement • in PEF from baseline. • Hyper-responsiveness: • Methacholine/histamine challenge • Exercise: A fall of 20% in PEF (or 15% in FEV1) measured • 5-10 minutes apart – before and then after cessation of exercise • (e.g. running for 6 minutes) • Diurnal Variation: • Diurnal Variation in PEF of more than 20% • Distinguishing between COPD and asthma when FEV shows obstruction: • Improvement of FEV1 from baseline (>12% and 200ml) • after a 2 week trial of oral prednisone (40mg daily)

12. Differentiating asthma and COPD

13. Other causes of airway obstruction

14. Causes of occupational asthma

15. B.ASSESSMENT OFSEVERITY OR CONTROL

18. C.ASTHMA TREATMENT • Preventative/Avoidance Measures • Pharmacotherapy

19. Preventative/Avoidance Measures • A. Avoid exposure to personal and second-hand tobacco smoke • B. Avoid contact with furry animals • C. Reduce pollen exposure • D. Reduce exposure to house dust mite • E. Avoid sensitisers and irritants (dust and fumes) which aggravate or cause asthma, especially in the workplace • F. Avoid food and beverages containing preservatives • G. Avoid drugs that aggravate asthma such as beta-blockers (including eye drops) and aspirin and non-steroidal anti-inflammatory drugs

20. PHARMACOTHERAPY • (A) RELIEVERS : • Act only on airway smooth muscle spasm • i.e. Cause BRONCHODILATION • symptoms acutely - cough • - SOB • - wheeze/tightness • Take when necessary

21. PHARMACOTHERAPY • (B) CONTROLLERS : • underlying INFLAMMATION • and/or cause prolonged bronchodilation • i.e. • mucosal swelling • • secretions • • irritability of smooth muscle • Take regularly, even when well • For ALL asthmatics, except mild intermittent

22. ASTHMA DRUG CLASSIFICATION

23. Key prescribing recommendations • All patients should be prescribed inhaled, short-acting ß2agonists such as salbutamol; 200mcg (2 puffs) as needed for use as symptom relief for acute asthma symptoms (Evidence A). • All patients should receive inhaled corticosteroids as baseline asthma treatment except those classified as mild intermittent asthma (Evidence A).

24. Inhaled Corticosteroids • Mainstay of Rx of chronic asthma • symptoms & lung function decline • • give twice daily regularly • • direct lung delivery = lower dose • • use of spacers ­ delivery & side effects • • safe 1000µg BDP/day (800µg Bud/day)

25. Inhaled Corticosteroids • Beclomethasone • • Beclate • Becotide • Becloforte • • Clenil • Viarox • Aerobec • Budesonide • • Inflammide • Budeflam • Fluticasone • • Flixotide • Flomist

26. Equivalent doses of inhaled steroid

27. RECOMMENDED ADD-ON Rx • 1. Add a LABA if asthma is not well controlled on low • dose ICS (Evidence A). This option is preferred to • doubling the dose of ICS; however, not all patients • respond to LABAs. Never use LABAs alone. • 2. An alternative is to double the dose of ICS or add • leukotriene modifiers (Evidence A) or slow-release • theophyllines (Evidence B) • 3. Oral corticosteroids should only be used as a • maintenance treatment with extreme caution. • 4. Referral to a specialist is recommended when asthma • is difficult to control

28. Long-Acting Beta-2 Agonists • Salmeterol • Formoterol • Combined with steroid • Serevent • Oxis • Foradil • Foratec • Seretide • Symbicord

29. Long-Acting Beta-2 Agonists • • cause bronchodilation for 12+ hours • • give twice daily regularly • • delayed onset of action - Salmeterol

30. Indications for Long-Acting Beta-Agonists • Patients with poor control despite moderate dose of inhaled steroids especially when: • They should not be used as monotherapy but in combination with inhaled steroids. • nocturnal asthma • wide variation in am & pm PEF • exercise-induced asthma

31. Leukotriene Receptor Antagonists • Montelukast - Singulair • Zafirlukast - Accolate • Advantages: • • Unique mode of action • • Oral form and “one dose fits all” • • Add-on effect when used with inhaled steroids • • Anti-inflammatory and anti-bronchoconstrictor

32. STEP-WISE Rx of ASTHMA • Only an option for those with mild intermittent asthma at diagnosis or who remain consistently well-controlled and treatment is progressively reduced STEP 1: • Inhaled beta-agonist PRN

33. STEP-WISE Rx of ASTHMA STEP 2: • Inhaled beta-agonist PRN • Low dose inhaled corticosteroid 250-500ug/day (BDP equivalent) • Start patients with mild chronic persistent asthma at this step

34. STEP-WISE Rx of ASTHMA STEP 3: • Inhaled beta-agonist PRN & • Low dose inhaled corticosteroid 250-500ug/day (BDP equivalent) & • Inhaled long-acting beta-agonist (PREFERRED) OR • Low dose inhaled corticosteroid 250-500ug/day (BDP equivalent) & • Oral leukotriene modifier OR • Moderate dose inhaled corticosteroid 500-1000ug/day (BDP equivalent)

35. STEP-WISE Rx of ASTHMA STEP 4: • Inhaled beta-agonist PRN & • Moderate dose inhaled corticosteroid 500-1000ug/day (BDP equivalent) & • Inhaled long-acting beta-agonist (PREFERRED) OR • Moderate dose inhaled corticosteroid 500-1000ug/day • Oral leukotriene modifier OR • Moderate dose inhaled corticosteroid 500-1000ug/day & • Oral SR theophylline BD

36. STEP-WISE Rx of ASTHMA STEP 5: • Inhaled beta-agonist PRN & • High dose inhaled corticosteroid >1000ug/day (BDP equivalent) & • Inhaled long-acting beta-agonist AND • Oral leukotriene modifier OR • Oral SR theophylline BD

37. STEP-WISE Rx of ASTHMA STEP 6: • Inhaled beta-agonist PRN & • High dose inhaled corticosteroid >1000ug/day (BDP equivalent) & • Inhaled long-acting beta-agonist PLUS • Oral leukotriene modifier PLUS • Oral SR theophylline BD AND/OR • Long term oral corticosteroids PLUS • SPECIALIST REFERRAL

38. Treatment Choices • Depend on: • • availability • • cost • • efficacy in individual patients • • patient preference • • side effect profile

39. Cost Compromises • • oral steroids vs. inhaled steroids • ~ long-term side effects: “save now, pay later” • • oral theophylline vs. inhaled beta-agonists • ~ less effective, more side effects, titration difficult • • short-acting vs. long-acting theophyllines • • short-acting vs. long-acting beta-agonists • • oral vs. inhaled long-acting beta-agonists • ~ less effective, more side effects • • MDIs ± spacers vs. dry powder devices

40. Therapy to avoid! • • sedatives & hypnotics • • cough syrups • • anti-histamines • • duplication of same type (eg. Ventolin + Berotec) • • combination tablets • • immunosuppressive drugs • • immunotherapy • • maintenance oral prednisone >10mg/day

41. AsthmaTreatmentAlgorithm

42. Asthma Treatment Algorithm

43. D.ACHIEVE AND MONITORCONTROL

44. Routine Asthma Questions • 1) How many times/week do asthma symptoms (cough, wheeze, SOB) affect you during the day? • 2) How many times/week do asthma symptoms disturb your sleep? • 3) How many times/week do you use your relievers? • 4) Has asthma caused time off work/school or interfered with your usual activities? • 5) Have you needed to attend as an emergency • since your last visit / over the last year?

45. Assessing control

46. Monitor Asthma Control

47. Managing partly/uncontrolled patients • Check the inhaler technique • Check adherence and understanding of medication • Consider aggravation by: • Exposure to triggers/allergens at home or work • Co-morbid conditions: GI reflux, rhinitis/sinusitis, cardiac • Medications: Beta-blockers, NSAIDs, Aspirin • Consider stepping up treatment • Consider need for short course oral steroids • Review self-management plan

48. ASSESS GOOD INHALER TECHNIQUE RINSE MOUTH AFTER INHALATION OF CORTICOSTEROIDS

49. ASSESS GOOD SPACER TECHNIQUE RINSE MOUTH AFTER INHALATION OF CORTICOSTEROIDS

50. PREDICTED PEF RATESIN ADULT WOMEN